China Evergrande New Energy Vehicle Group Limited

China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.

China Evergrande New Energy Vehicle Group Limited trades as EVGRF on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.34B of revenue and -$11.93B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

China Evergrande New Energy Vehicle Group Limited can be compared against peers such as American Oncology Network, Inc., Benchmark Holdings plc, Mayne Pharma Group Limited, Medical Facilities Corporation, M1 Kliniken AG, hVIVO plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.17M, beta of 1.00, and return on equity of +31.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EVGRF currently shows total debt of $26.82B and beta of 1.00. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://health.evergrande.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.